VACCINATION with BCG has become established in many countries as an effective measure for the control of tuberculosis. There have been marked differences of opinion in this country as to the value of BCG vaccine, but the recent report of the Medical Research Council (1956) on vaccination of school leavers has shown it to have proved of value under certain conditions. A liquid vaccine was used in this trial-up to now the universally accepted form of BCG administration, except in Japan.
It has been realized that the liquid vaccine has certain disadvantages. First, the culture has to be closely watched for changes in antigenicity and virulence due to the continuous subculturing at tento fourteen-day intervals, and elaborate tests are necessary for this purpose. More important for the practical use of the vaccine are two other handicaps: it has only a limited life of about fourteen days and there is no direct evidence as to the antigenicity and safety of the vaccine when it is used. The vaccine consists of live bacteria and contains no antiseptics, so that slowly-growing contaminants would be difficult to detect by conventional sterility tests. The biological control of BCG is a long process. Apart from the safety tests, which include those for absence of virulence in the BCG, it is important to establish that the particular batch contains the required number of viable organisms. A much higher content is liable to produce untoward local reactions (ulcers, lymphadenitis); a low content may result in an unsatisfactory tuberculin conversion rate. Such variations in effect between batches of liquid vaccine have been noted.
It has been known that bacteria can be freeze-dried without affecting their biological characteristics, and it was obviously sensible to try to apply this technique to BCG, particularly in view of the considerable advances made in freeze-drying techniques as used in the preparation of antibiotics.
An effective freeze-dried BCG vaccine should have the following advantages over the liquid type: (a) Stability.-The vaccine would under suitable conditions be stable for at least one year and be available for use at any time during that period. (b) Uniformity.-The vaccine could be standardized in terms of viable bacteria, so avoiding undesirable variations between batches. (c) Safety and potency.-Each batch can be submitted to safety tests and to potency tests to establish its antigenicity before release.
GLAXO FREEZE-DRED BCG VACCINE A freeze-dried vaccine should be prepared in such a manner that it reconstitutes on addition of fluid to a homogeneous suspension of cells with a minimum of clumping. The medium in which the bacteria are dried should be non-antigenic and not liable to cause any reaction. In the past vaccines have been prepared in serum, 50 % glucose, 1 % sucrose, various concentrations of lactose, &c., but most of these have disadvantages. After prolonged trials we have chosen as a suspending agent an aqueous solution of 8-3 % of dextran with 7-5 % glucose. The vaccine (Ungar et al., 1956 ) is prepared from the same strain of BCG as that used in the M.R.C. trial; in our experience there is no essential difference in the strains of BCG used in various laboratories and freeze-dried vaccine can be prepared from any of them.
The strain is grown in a submerged culture in Sauton's medium, with addition of 1/4,000 w/v Triton "WR 1339", at a temperature of 370 C. for nine days. The growth is centrifuged and the deposit reconstituted in the dextran-glucose medium and standardized to a final con-Section of Comparative Mediwone 381 centration by opacity measurements in the Spekker photometer. The vaccine is filled into special moulded ampoules, then freeze-dried and sealed in vacuo. After preparation it is tested for its content of viable cells and on laboratory animals for safety and potency. These tests take about ten weeks: only after their conclusion are batches released for general distribution. The freeze-dried material is easily reconstituted for intradermal use by adding 1 ml. of either sterile water or physiological saline to the ampoule.
The viability count of the reconstituted freeze-dried vaccine is worth mentioning, because it is this property of the vaccine that it is particularly important to standardize. During the process of freeze-drying, depending on conditions, a proportion of the suspension survives; in our technique it is about one-tenth of the bacteria originally present. We found that a modification of O'Hea's method (1955) was the most suitable for our purpose; in this 0 02 ml.
drops from a platinum dropping pipette are applied to the surface of the medium held in small bottles (7 ml. bijou bottles) filled with 10% blood agar medium. The vaccine is diluted in Sauton's medium, with 1/4,000 Triton added to inhibit aggregation, and tenfold dilutions from 10-3 to 10-' are made in duplicate from each batch. The diluted solutions are incubated in six bottles of medium, and an average of twelve counts is taken. The method, as used in our laboratory, seems to give reproducible results, and we believe that it enables us to issue vaccines of a constant potency and with satisfactory keeping properties for at least twelve months when stored below 20°C.
BIOLOGICAL STUDrEs IN ANmALs
One of the basic properties of the BCG vaccine is induction of tuberculin-sensitivity in the inoculated animal. The generally accepted view being that tuberculin allergy is a convenient index of acquired resistance, we have used the tuberculin conversion test to assess the quality of the vaccine. It has occasionally been stated that the freeze-dried vaccine is slower in inducing tuberculin allergy than is a freshly prepared fluid vaccine. We have found that the time of the appearance of the reaction to tuberculin, and the intensity of the reaction, depend on the number of viable organisms in the vaccinating dose (Table I) . Similarly, the size of the 
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Vaccination dose and route: 0 1 ml. injected intradermally. 0 indicates less than 2 mm. 0 Heat killed 0 0 0 0 0 0 0 = No lesion. 1 = Small < 4 mm. lesion with small scab. 2 = Lesion 4-6 mm. diameter with firm 2-3 mm. scab. 3 = Lesion 7-10 mm. diameter-with firm 5-6 mm. scab and some ulceration. 4 = Lesion > 10 mm. diameter with firm > 6 mm. scab, ulceration and deep necrosis.
vaccination papule after inoculating 0-1 ml. of the vaccine intracutaneously depends on the number of viable bacteria. Table II shows that the size of the local lesion was related to the viable cell content. By standardizing our vaccine to a required strength, we are able to issue biologically active vaccines and at the same time to avoid the danger of excessive local or regional (lymphadenitis) reactions, such as have occasionally occurred with liquid vaccines. Protection tests in animals vaccinated with BCG are still in the experimental stage. No satisfactory answer can as yet be given from experiments on vaccinated guinea-pigs or mice subsequently challenged with virulent tubercle bacilli. An indirect method of assessing acquired resistance by measuring the radio-activity of disintegrated labelled mycobacteria in vaccinated and controlled animals is under investigation. This procedure might lead to a method for quantitative evaluation of the vaccine's efficacy.
BIOLOGICAL STUDIES IN CHILDREN
When we began our investigations we had no information on certain essential questions. They were:
(a) What should be the content of viable organisms in the vaccine to give a satisfactory tuberculin conversion without untoward reactions?
(b) Does the biological effect of the vaccine diminish with the time of its storage even though the viable count does not alter?
(c) Should the dose for babies be different from that for older children or adults? (d) Is the vaccine suitable for different routes of administration? It is a great pleasure to state that, thanks to the support and unceasing efforts of Professor W. Gaisford, Dr. M. Griffiths, Dr. J. Lorber, Dr. W. Hartston, Professor F. Heaf, and more recently of the M.R.C. Committee on Tuberculosis and particularly Drs. D. G. Evans and T. Osborne, we have been able to formulate the correct composition of the freeze-dried vaccine as an effective and safe antigen for intracutaneous vaccination.
Lorber and his team (1956) , and Griffiths and Gaisford (1956) in their independent trials, have established that the freeze-dried vaccine is an effective antigen for young babies, as is the fluid Danish vaccine. They have also confirmed the considerable practical advantages of the dried over the liquid vaccine for use in clinics. Similar conclusions to those of Griffiths and Gaisford were drawn by Lorber and coworkers (1957); Table III (From Lorber et al., 1957.) (b) In Lorber's series, vaccines were five to ten months old when vaccinations were begun. There was no evidence of deterioration, as judged either by the size of local reaction or by the extent of tuberculin response, in babies vaccinated with vaccines stored at room temperature throughout the four months' trial. Groups of infants vaccinated with it either at the beginning or at the end of the trial period gave the same response.
(c) The dried vaccine was standardized at the early stages with the primary object of using it for vaccinating babies. The first intimation that the same product might be suitable also for vaccinating school leavers came from Dr. W. Hartston, Tuberculosis Officer of the London County Council. In his preliminary trials Dr. Hartston compared Batch 62 with the Danish liquid vaccine and found that the responses after intradermal inoculation of either were similar. Since then, use of the freeze-dried vaccine has been extended to school leavers and reports from Dr. Hartston, Professor Heaf, Dr. Lorber and Dr. Griffiths and others have established that the original vaccine is also suitable for immunizing school leavers and contact cases in adults. This finding indicates that a single type of vaccine can be issued for general use.
(d) The intracutaneous vaccine is not the only type that has been available. My colleagues, Dr. P. W. Muggleton and Miss J. P. Farmer, have modified the freeze-dried technique to enable them to produce alternative types of freeze-dried vaccines suitable for oral use or for percutaneous administration by the multiple puncture method. The latter has been studied by Professor Heaf and by Dr. Hartston, whose experience seems to indicate that the multiple puncture method will give a satisfactory tuberculin conversion rate without causing any of the marked local lesions sometimes seen after intracutaneous inoculations.
There are many aspects of BCG vaccination still open to discussion and I can only briefly mention them. One is the question of the optimal age for vaccination. PTediatricians would like to have vaccination begun before puberty. Occasionally doubts are expressed about the safety of the vaccine, but the reports of WHO on BCG mass imunization should convince any unbiased reader of its innocuousness. The opinion has recently been expressed that BCG has lost its value in communities with a high standard of living, because of the continuous decline of the tuberculosis mortality rate. This argument seems, however, to ignore the fact that the morbidity from the disease and the number of new cases of tuberculosis is still surprisingly high (report of the Medical Advisory Committee of the Research Foundation, 1957) . It has to be admitted that the wider use of vaccination involves a reduction in the diagnostic value of the tuberculin test. Clinicians and epidemiologists will have to decide whether or not the extent of the protection afforded against tuberculosis makes this sacrifice worth while.
